china is host to 70 percent of all car cell therapy trials registered in 2017 and the first four months of 2018 (150 out of 214).
.following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.